Form 4: Minerva Neurosciences CEO Acquires 105,000 Stock Options

Minerva Neurosciences CEO, Remy Luthringer, was granted 105,000 employee stock options on December 5, 2024.

Summary

• Remy Luthringer, CEO of Minerva Neurosciences, Inc., acquired 105,000 employee stock options on December 5, 2024.
• The options have an exercise price of $2.12 per share.
• The options vest 25% on December 5, 2025, and then in equal quarterly installments over the following three years.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term performance of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 25% after one year and then quarterly over three years is a typical vesting schedule for stock options.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning the CEO's interests with the company's long-term success.

Key Dates

Keywords

stock options, insider trading, executive compensation, Minerva Neurosciences, NERV, Remy Luthringer